Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Achilles Therapeutics Plc (ACHL)

Achilles Therapeutics Plc (ACHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,394
  • Shares Outstanding, K 39,155
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,100 K
  • 60-Month Beta 0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.35
Trade ACHL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.56
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -4.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5800 +20.25%
on 11/09/22
2.1387 -11.16%
on 10/26/22
-0.1000 (-5.00%)
since 10/25/22
3-Month
1.5800 +20.25%
on 11/09/22
3.3000 -42.42%
on 08/29/22
-1.3400 (-41.36%)
since 08/25/22
52-Week
1.5800 +20.25%
on 11/09/22
5.6500 -66.37%
on 12/23/21
-3.2900 (-63.39%)
since 11/24/21

Most Recent Stories

More News
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near...

ACHL : 1.9000 (+6.15%)
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe

Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.

AZN : 66.17 (+0.08%)
ATRA : 4.18 (+0.24%)
APLS : 50.96 (+2.97%)
ACHL : 1.9000 (+6.15%)
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

ALNY : 212.72 (+2.03%)
ATRA : 4.18 (+0.24%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

ATRA : 4.18 (+0.24%)
ALLO : 10.77 (+1.60%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why

Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.

BPMC : 44.89 (+0.13%)
DCPH : 15.93 (+3.37%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

AZN : 66.17 (+0.08%)
APLS : 50.96 (+2.97%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

ATRA : 4.18 (+0.24%)
ISEE : 21.56 (-0.83%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

GILD : 86.26 (+0.98%)
ATRA : 4.18 (+0.24%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

HZNP : 78.28 (+0.97%)
ATRA : 4.18 (+0.24%)
IMVT : 13.22 (-0.60%)
ACHL : 1.9000 (+6.15%)
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

ATRA : 4.18 (+0.24%)
ORIC : 3.50 (-3.58%)
ACHL : 1.9000 (+6.15%)
IMRX : 6.57 (+3.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company. It engages in developing precision T cell therapies to treat solid tumors. Achilles Therapeutics plc is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 2.2635
2nd Resistance Point 2.1367
1st Resistance Point 2.0184
Last Price 1.9000
1st Support Level 1.7733
2nd Support Level 1.6465
3rd Support Level 1.5282

See More

52-Week High 5.6500
Fibonacci 61.8% 4.0953
Fibonacci 50% 3.6150
Fibonacci 38.2% 3.1347
Last Price 1.9000
52-Week Low 1.5800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar